This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Souazé, F. Articles by Forgez, P. Search for Related Content PubMed PubMed Citation Articles by Souazé, F. Articles by Forgez, P.

Expression of Neurotensin and NT1 Receptor in Human Breast Cancer: A Potential Role in Tumor Progression

¹ Institut National de la Sante et de la Recherche Medicale U673 and UPMC, Hôpital Saint-Antoine; ² Unité de Gynécologie, AP-HP, Hôtel-Dieu de Paris, Paris, France and ³ Laboratory of Experimental Cancerology, Ghent University Hospital, Ghent, Belgium

Requests for reprints: Patricia Forgez, Institut National de la Sante et de la Recherche Medicale U673 and UPMC, Hôpital Saint-Antoine, Bâtiment Raoul Kourilsky, 184 rue du Faubourg St-Antoine, 75571 Paris Cedex 12, France. Phone: 33-1-49-28-46-69; Fax: 33-1-44-74-93-18; E-mail: forgez{at}st-antoine.inserm.fr.

Emerging evidence supports neurotensin as a trophic and antiapoptotic factor, mediating its control via the high-affinity neurotensin receptor (NT1 receptor) in several human solid tumors. In a series of 51 patients with invasive ductal breast cancers, 34% of all tumors were positive for neurotensin and 91% positive for NT1 receptor. We found a coexpression of neurotensin and NT1 receptor in a large proportion (30%) of ductal breast tumors, suggesting a contribution of the neurotensinergic signaling cascade within breast cancer progression. Functionally expressed NT1 receptor, in the highly malignant MDA-MB-231 human breast cancer cell line, coordinated a series of transforming functions, including cellular migration, invasion, induction of the matrix metalloproteinase (MMP)-9 transcripts, and MMP-9 gelatinase activity. Disruption of NT1 receptor signaling by silencing RNA or use of a specific NT1 receptor antagonist, SR48692, caused the reversion of these transforming functions and tumor growth of MDA-MB-231 cells xenografted in nude mice. Our findings support the contribution of neurotensin in human breast cancer progression and point out the utility to develop therapeutic molecules targeting neurotensin or NT1 receptor signaling cascade. These strategies would increase the range of therapeutic approaches and be beneficial for specific patients. (Cancer Res 2006; 66(12): 6243-9)

This article has been cited by other articles:

				Y. Heakal and M. Kester Nanoliposomal Short-Chain Ceramide Inhibits Agonist-Dependent Translocation of Neurotensin Receptor 1 to Structured Membrane Microdomains in Breast Cancer Cells Mol. Cancer Res., May 1, 2009; 7(5): 724 - 734. [Abstract] [Full Text] [PDF]

				P. Broet, S. Camilleri-Broet, S. Zhang, M. Alifano, D. Bangarusamy, M. Battistella, Y. Wu, M. Tuefferd, J.-F. Regnard, E. Lim, et al. Prediction of Clinical Outcome in Multiple Lung Cancer Cohorts by Integrative Genomics: Implications for Chemotherapy Selection Cancer Res., February 1, 2009; 69(3): 1055 - 1062. [Abstract] [Full Text] [PDF]

				M. Gong, L. Meng, B. Jiang, J. Zhang, H. Yang, J. Wu, and C. Shou p37 from Mycoplasma hyorhinis promotes cancer cell invasiveness and metastasis through activation of MMP-2 and followed by phosphorylation of EGFR Mol. Cancer Ther., March 1, 2008; 7(3): 530 - 537. [Abstract] [Full Text] [PDF]

				Z. Wei and H. Li A Markov random field model for network-based analysis of genomic data Bioinformatics, June 15, 2007; 23(12): 1537 - 1544. [Abstract] [Full Text] [PDF]